July 18th 2022
Before closing out their discussion on early-stage HER2+ breast cancer, expert oncologists define the value of escalating or deescalating therapy.
July 11th 2022
Subject matter experts in breast oncology discuss ongoing clinical trials in early-stage HER2+ breast cancer that focus on perioperative therapies.
Expert oncologists share their perspectives on when it would be appropriate to consider neratinib therapy in early-stage HER2+ breast cancer.
July 8th 2022
A leader in breast medical oncology reflects on key clinical trial updates presented at the 2022 ASCO Annual Meeting, and their implications for clinical practice.
Highlighting the importance of a multidisciplinary approach to care in HER2+ mBC, Vijayakrishna Gadi, MD, PhD, describes the value of effective consultation with neurooncologists and radiation oncologists for CNS metastases.
July 4th 2022
A brief discussion on the role of trastuzumab emtansine, T-DM1, in patients with early-stage HER2+ breast cancer.
Panelists review clinical data behind subcutaneous HP therapy in early stage HER2+ breast cancer and elucidate the real-world use of this approach.
July 1st 2022
An expert oncologist reviews key considerations in selecting and sequencing treatment appropriately in patients with HER2+ breast cancer and CNS metastases, including challenges associated with treating leptomeningeal disease.
Vijayakrishna Gadi, MD, PhD, discusses factors to consider in the first- and second-line management of HER2+ mBC with particular emphasis on treatment selection, safety, and sequencing.
June 27th 2022
Shared insight on the optimal use of HER2 dual-blockade strategies in patients with early stage HER2+ breast cancer.
Expert oncologists review adjuvant treatment strategies in early stage HER2+ breast cancer and consider when observation alone would be appropriate.
March 10th 2022
Closing out their discussion on novel therapies for HER2+ metastatic breast cancer, experts share excitement for future clinical trials and strategies.
March 2nd 2022
A panel of experts briefly reviews the treatment options available for patients with ER+, HER2+ metastatic breast cancer.
Expert panelists discuss the optimal management patients with special subsets of HER2+ metastatic breast cancer, such as HR+ or HER2-low disease.
February 23rd 2022
Shared insight on the potential role for surgery in the setting of HER2+ metastatic breast cancer in the context of pharmacologic therapy.
Rounding out their conversation on SABCS 2021, experts discuss small molecule–based treatment strategies for relapsed/refractory HER2+ metastatic breast cancer.
February 16th 2022
Considering data from the SABCS 2021 annual meeting, experts discuss novel combination strategies for relapsed/refractory HER2+ metastatic breast cancer.
A brief review of updated data from HER2CLIMB and discussion on which agents may be best for treating patients with CNS disease.
February 9th 2022
Experts discuss the role of novel therapies in relapsed/refractory HER2+ metastatic breast cancer accounting for results from recent clinical trial.
Shared insight on the roles of trastuzumab emtansine and trastuzumab deruxtecan in relapsed/refractory HER2+ metastatic breast cancer.